The outlook of companies tied to Sildenafil's past presents a challenging investment scenario . While the initial boom generated substantial profits , generic copies have significantly diminished revenue. Investing in related pharmaceutical firms now requires a thorough assessment of patent rights , evolving healthcare trends , and the potential fo